|
Name |
(4S,8aR,12S,12aR)-12-Hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-2H-3-benzoxecine-2,9(1H)-dione
|
Molecular Formula | C14H20O4 | |
IUPAC Name* |
(4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione
|
|
SMILES |
C[C@H]1CCCC[C@@H]2[C@@H](CC(=O)O1)[C@H](C=CC2=O)O
|
|
InChI |
InChI=1S/C14H20O4/c1-9-4-2-3-5-10-11(8-14(17)18-9)13(16)7-6-12(10)15/h6-7,9-11,13,16H,2-5,8H2,1H3/t9-,10+,11+,13-/m0/s1
|
|
InChIKey |
WTQWDNIIFGEBSZ-WGBDABJCSA-N
|
|
Synonyms |
Sch 642305; SCH-642305; CHEMBL453428; CHEBI:66181; (+)-sch 642305; (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione; (4S,8aR,12S,12aR)-12-Hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-2H-3-benzoxecine-2,9(1H)-dione; 643747-04-0; 2H-3-Benzoxecin-2,9(1H)-dione, 4,5,6,7,8,8a,12,12a-octahydro-12-hydroxy-4-methyl-, (4S,8aR,12S,12aR)-; DTXSID901045496; BDBM50250671; Q15424766; 4-Hydroxy-8-methyl-4a,5,8,9,10,11,12,12a-octahydro-4H-7-oxa-benzocyclodecene-1,6-dione; (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a-hexahydro-1H-benzo[d]oxecine-2,9(12H,12aH)-dione; rel-(4R,8aS,12R,12aS)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-2H-3-benzoxecine-2,9(1H)-dione
|
|
CAS | NA | |
PubChem CID | 637324 | |
ChEMBL ID | CHEMBL453428 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 252.31 | ALogp: | 1.4 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 63.6 | Aromatic Rings: | 2 |
Heavy Atoms: | 18 | QED Weighted: | 0.671 |
Caco-2 Permeability: | -4.784 | MDCK Permeability: | 0.00001910 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.048 |
Human Intestinal Absorption (HIA): | 0.025 | 20% Bioavailability (F20%): | 0.126 |
30% Bioavailability (F30%): | 0.977 |
Blood-Brain-Barrier Penetration (BBB): | 0.253 | Plasma Protein Binding (PPB): | 79.26% |
Volume Distribution (VD): | 1.178 | Fu: | 21.99% |
CYP1A2-inhibitor: | 0.179 | CYP1A2-substrate: | 0.835 |
CYP2C19-inhibitor: | 0.089 | CYP2C19-substrate: | 0.365 |
CYP2C9-inhibitor: | 0.088 | CYP2C9-substrate: | 0.896 |
CYP2D6-inhibitor: | 0.141 | CYP2D6-substrate: | 0.62 |
CYP3A4-inhibitor: | 0.042 | CYP3A4-substrate: | 0.166 |
Clearance (CL): | 15.323 | Half-life (T1/2): | 0.903 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.207 |
Drug-inuced Liver Injury (DILI): | 0.028 | AMES Toxicity: | 0.597 |
Rat Oral Acute Toxicity: | 0.374 | Maximum Recommended Daily Dose: | 0.599 |
Skin Sensitization: | 0.936 | Carcinogencity: | 0.5 |
Eye Corrosion: | 0.031 | Eye Irritation: | 0.899 |
Respiratory Toxicity: | 0.521 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002164 | 0.524 | D07GRH | 0.278 | ||||
ENC002181 | 0.524 | D0C7JF | 0.258 | ||||
ENC002098 | 0.516 | D0K7LU | 0.253 | ||||
ENC002200 | 0.516 | D0D2VS | 0.247 | ||||
ENC001860 | 0.493 | D00YWP | 0.244 | ||||
ENC002735 | 0.493 | D0K0EK | 0.239 | ||||
ENC003475 | 0.449 | D06WTZ | 0.238 | ||||
ENC002063 | 0.446 | D0D1SG | 0.235 | ||||
ENC004377 | 0.429 | D0H0ND | 0.234 | ||||
ENC003404 | 0.429 | D00ZFP | 0.230 |